AlphAIalphai — Financial news for AI agents
finanznachrichten.deJUN 184 min read$ALVONeutralMed

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Alvotech (NASDAQ: ALVO) said it closed its underwritten public offering on June 17, 2026, selling 26,066,667 ordinary shares at $3.75 each, including full exercise of the underwriters’ option for 3,400,000 additional shares. Gross proceeds to the company were about $98 million. A concurrent $67 million private placement of 17,826,666 shares is expected to close around June 25, bringing total gross proceeds to about $165 million.

AI DeskJune 18, 2026
Source · finanznachrichten.de
AI analysis
Relevance
8/10
Novelty
8/10
Actionability
Med
Sentiment · $ALVO
Neutral
Timing
after-hours/early premarket today following June 17 closing; private placement expected to close around June 25
Market alignment
capital raise at fixed $3.75/share likely viewed as dilution-neutral-to-negative, with sentiment improving if investors focus on funding runway
Why this matters for $ALVO

The capital raise increases near-term funding visibility for biosimilar development but adds dilution risk; traders should reassess balance-sheet runway vs. share count impact.

Relevance context

Alvotech closed a $98M underwritten public offering at $3.75/share and expects ~$67M from a concurrent private placement, totaling ~$165M gross proceeds.

Price-impact prediction

Near-term pressure possible from dilution expectations, partially offset by funding clarity; direction likely depends on whether investors view proceeds as sufficient for pipeline milestones.

Background

Alvotech announced and has now closed an underwritten public offering, alongside a concurrent EEA-qualified private placement exempt from US registration requirements.

Why it matters

The transaction provides ~$165M gross funding for biosimilar development, working capital, and potential corporate actions, but increases share count (43.9M new shares delivered post-closing of the concurrent placement).

Market relevance

Deal terms (price, share count, gross proceeds) are concrete and can drive near-term trading via dilution expectations and funding-runway reassessment.

Market effects

Sector

Biosimilar peers may face read-across on financing conditions and dilution appetite for development-stage biotech.

Regional

Limited direct regional impact; deal is US-listed with EEA-qualified investor private placement.

Global

Global biosimilar funding narrative may influence investor risk appetite for non-innovator pharma development programs.

Alternative perspectives

Contrarian view

If the proceeds are earmarked for specific de-risking milestones (clinical/pre-commercialization and IP enforcement), the market may re-rate the stock despite dilution.

Overlooked factors

Watch for the private placement closing timing (June 25) and any subsequent use-of-proceeds updates; dilution impact depends on net proceeds after fees and how quickly management converts funding into measurable pipeline progress.

Key entities

  • company
    Alvotech

    NASDAQ-listed biosimilar developer that closed a $98M public offering and expects ~$67M from a concurrent private placement.

  • bank
    BofA Securities

    Joint book-running manager for the offering.

  • bank
    Jefferies

    Joint book-running manager for the offering.

  • bank
    Evercore ISI

    Joint book-running manager for the offering.

Read at source← All news

Related articles

JUN 18
$ALVOMed

Amended: Alvotech Announces $125 Mln Public Offering, Concurrent Private Placement

Alvotech (ALVO) said it is launching an underwritten public offering of ordinary shares and a concurrent private placement, not an IPO. Net proceeds are expected at about $125 million, to fund biosimilar development and general corporate purposes. Underwriters have a 30-day option to buy up to 15% more shares. BofA Securities, Jefferies and Evercore ISI are joint book-runners.

rttnews.com2 min
JUN 16
$ALVOMedAI 9/10

Alvotech Prices $152 Million Offering To Advance Biosimilar Portfolio; Stock Down

Alvotech (ALVO) priced a combined $152 million capital raise via an underwritten public offering and a concurrent private placement, according to the company. The public offering sells 22.67M shares at $3.75 each for about $85M gross proceeds (about $98M if underwriters’ option is exercised). A private placement sells 17.83M shares for about $67M. Net proceeds will fund biosimilar development and corporate needs; shares closed at $4.24 Monday.

rttnews.com4 min
JUN 16
$ALVOMedAI 8/10

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech (NASDAQ: ALVO) priced a $152 million public offering of 22,666,667 ordinary shares at $3.75 each, with an underwriters’ 30-day option to buy up to 3,400,000 more shares. Expected gross proceeds are about $85 million, or $98 million with the option. A concurrent private placement will sell 17,826,666 shares for about $67 million. Net proceeds will fund biosimilar development and corporate purposes.

portal.sina.com.hk4 min
JUN 16
$ALVOMedAI 8/10

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech (NASDAQ: ALVO) priced a $152 million underwritten public offering of 22,666,667 ordinary shares at $3.75 each, expected to close June 17, 2026. Gross proceeds are about $85 million, rising to ~$98 million if underwriters buy an extra 3.4 million shares. A concurrent private placement will sell 17,826,666 shares for ~$67 million gross. Total gross proceeds: ~$152 million (~$165 million with the option).

manilatimes.net4 min